DGAP-News

Vita 34 introduces new Chief Financial Officer at the Annual General Meeting - Seite 2

During his company presentation, CEO Jakub Baran went into detail about the Group's new direction following the merger between Vita 34 and PBKM FamiCord and highlighted the enormous potential that lies in the newly expanding business areas of Cell & Gene Therapies and CDMO. "In these new, rapidly developing business areas, Vita 34 will in the future act as a service provider for other pharmaceutical companies on the one hand, and develop its own drugs and therapies on the other," explained CEO Jakub Baran. "We already generate five percent of our group revenues with these areas today. The clinical trials required for the development of the therapies are already advanced and therefore already offer significant potential for a fundamental reassessment of the Group." At the same time, the CEO swore in the shareholders to a year of transition. "First of all, we have to cope with the fact in our core business that the environment characterized by COVID-19, war turmoil and inflation holds and will hold numerous imponderables for Vita 34, and we are therefore facing a noticeable slowdown in our day-to-day business. Furthermore, we have only made a part of the required investments in the new expanding business areas, which is why extensive further investments will also be necessary in the current financial year 2022, financed from our nevertheless overall stable core business," Jakub Baran said. "We are confident that our efforts in the now and today will pay off to the maximum for the future of our Group. "

In detail, the items on the agenda were voted on with the following percentage approval of voting shares:

Agenda item 2:     99.0 %
Agenda item 3 a:  95.2 %
Agenda item 3 b:  98.8 %
Agenda item 3 c:  99.0 %
Agenda item 3 d:  95.2 %
Agenda item 3 e:  98.8 %
Agenda item 4:     94.4 %
Agenda item 5:     96.3 %
Agenda item 6:   100.0 %
Agenda item 7 a:  99.0 %
Agenda item 7 b:  99.4 %
Agenda item 8:     99.2 %
Agenda item 9:     99.3 %
Agenda item 10:   82.1 %
Agenda item 11:    99.6 %
Agenda item 12:    96.3 %
Agenda item 13:    99.8 %

Further details on the agenda items voted on are available for download on the website of Vita 34 AG at https://ir.vita34.de/investor-relations/hauptversammlung/hauptversammlung-2022/.